The report provides guidance for the 2024–2025 COVID-19 vaccination strategy from the Advisory Committee on Immunization Practices (ACIP). The methodology included reviewing data in 40 public meetings since June 2020. ACIP assessed vaccine efficacy, safety, and cost-effectiveness using the GRADE system. The analysis found that updated vaccines offer moderate protection against severe disease, hospitalization, and death, although their effectiveness diminishes over time. Vaccination is advised for everyone aged six months and older, with special focus on high-risk populations such as the elderly and immunocompromised individuals. Economic evaluations show that vaccines are most cost-effective for those aged 65 and older. The report concludes that the 2024–2025 vaccines, which target the currently circulating Omicron strains (JN.1 and KP.2), are essential for ongoing protection and reducing severe outcomes, with a priority on ensuring equitable access

Click here to read more